October 16, 2023
Biotechnology company Longeveron Inc. and its investors on Monday saw a Miami federal judge give a final nod to a $1.4 million settlement agreement that ends claims the company overhyped the prospects for a drug it was developing as it was going public.
May 01, 2023
A proposed class of investors in biotechnology company Longeveron Inc. has renewed its bid for an initial green light for a nearly $1.4 million settlement deal with the company after a federal judge in Miami earlier rejected their proposed plaintiffs' service award and requested revisions to their plans to formally request an attorney fee.
February 08, 2022
The Rosen Law Firm PA will represent a proposed class of investors in biotechnology company Longeveron Inc. in a suit accusing the company of overstating the prospects for a therapeutic product the company was testing as it made $24.7 million off of an initial public offering.
September 14, 2021
A biotechnology company cofounded by one of South Florida's most prominent real estate developers has been hit with a proposed securities class action claiming the company made false and misleading statements about a key product in the months leading up to and following its February initial stock offering.